Skip to content

Human Factoring Validation of Pulsenmore ES Device

Human Factoring Validation Testing of the Pulsenmore ES Home Ultrasound Monitoring Device for Conducting Fetal Scans During Pregnancy

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06567067
Enrollment
57
Registered
2024-08-22
Start date
2023-02-09
Completion date
2023-12-21
Last updated
2024-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy Related

Brief summary

The goal of this study is to conduct human factors validation testing with the Pulsenmore ES home Ultrasound device in the video-guided mode of operation (participants) and the clinician-guided mode of operation (participants and healthcare professionals (HCP)) to evaluate whether the device/user interface can be used by the intended users without any serious issues or errors under that intended use and actual use conditions. The intended users will be qualitatively assessed via observation and cognitive debrief and usability testing methodology. Participants will be remotely observed during the video-guided fetal scanning actual process and participants and HCPs will be remotely observed during the clinician-guided fetal scanning actual process.

Interventions

DEVICEPulsenmore ES home ultrasound

Fetal Ultrasound scanning using Pulsenmore ES device followed with an interview by a human factoring researched

Sponsors

PulseNmore
Lead SponsorINDUSTRY

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

for participants: * The participant has voluntarily provided and signed the informed consent form (ICF) * The participant has voluntarily provided authorization and signed the Videography and Photography Release form * The participant is able to speak, read, write and comprehend US English and resides in the United States of America * The participant to have adequate communications skills * Pregnant women \> 18 years of age * A singleton gestation * Gestational age between 14 to 38 weeks with a prior scan demonstrating fetal viability and confirming dates * Maximum BMI of 40 * Willing and able to participate in a 60-75 min video and is willing to be audio recorded for the post-procedure interview Inclusion criteria for HCP: * The HCP has voluntarily provided and signed the HCP consent information sheet (CIS) * The HCP has voluntarily provided authorization and signed the HCP Videography and photography Release form * The HCP is able to speak, read, write and comprehend US English and resides in the United States of America. * The HCP has adequate communications skills * The HCP is willing and able to participate in one 60 min video call and is willing to be audio recorded during the interview.

Exclusion criteria

for participants: * Multiple gestation * Skin problem(s) in the abdominal area (such as wounds, cuts in the skin and skin rash) * The participant has a visual or hearing impairment, and/or a condition that affects her motor and/or cognitive skills, that would prevent her from independently performing a fetal ultrasound scan at home * The participant has a language barrier that can affect the communication and compliance to the usability study requirement * Uncontrolled and untreated psychiatric conditions for a minimum of 6 months prior to screening, * Alcohol or drug dependence with current symptoms * Previous Pulsenmore ES trials and have previously used the Pulsenmore ES device * Known fetal and genetic anomalies.

Design outcomes

Primary

MeasureTime frameDescription
Safety issues while using Pulsenmore ES deviceOne dayAny safety issue, either serious that could cause serious injury or death to the user, or non serious
User error while using Pulsenmore ES deviceOne dayAny user interface issues reported by study participants and HCPs that can cause delay in diagnosis or treatment

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026